Patient Perceptions of FDA Approval: Gaps in Education or Variation in Values?

Area of Science:

• Neurology
• Regulatory Science
• Patient-Reported Outcomes

Background:

• Multiple sclerosis (MS) treatments have advanced with disease-modifying therapies (DMTs).
• The Food and Drug Administration (FDA) oversees the approval process for these critical medications.
• Patient perspectives on regulatory processes are vital for understanding treatment acceptance and trust.

Purpose of the Study:

• To evaluate how individuals with MS perceive the FDA's role and approval procedures for DMTs.
• To identify factors influencing patient comfort with newly approved MS therapies.
• To determine who patients believe should represent their interests in drug approval discussions.

Main Methods:

• A web-based survey was distributed to individuals living with MS.
• Survey items assessed perceptions of the FDA's function, approval criteria, and representation in decision-making.
• Data were analyzed comparing responses from those who have and have not used DMTs.

Main Results:

• Over 3,000 respondents participated, with most understanding the FDA's general role, but only half grasping the risk-benefit balance.
• Significant differences in perceptions emerged between DMT users and non-users.
• Comfort with uncertainty regarding new therapies correlated with specific benefit and side effect considerations.

Conclusions:

• Patient views on FDA processes and representation for MS DMTs differ based on prior treatment experience.
• Recognizing diverse patient values is crucial for regulatory bodies.
• Educational initiatives are necessary to enhance understanding of the FDA's mission and reliability.